Oscity BioSciences

Accelerating Innovation-Oscity BioSciences pioneers innovative natural processes that unlock the full therapeutic potential of the human endocannabinoid system.

[Oscity BioSciences @oscitybiosci]

Oscity BioSciences is honored to announce that CEO Christopher St. Pierre will serve as a panelist on the Science Meets Strategy session at the BIO Alabama 2026 Annual Conference.

The panel brings together leaders from research institutions, investment, entrepreneurship, and industry to examine how scientific advances are translated into commercial and clinical impact. For Alabama’s growing bioscience community, these discussions help strengthen the connections between discovery, strategy, and the partnerships needed to move promising technologies forward.

As an Alabama-based company focused on high-purity cannabinoid technologies for growing therapeutic applications, Oscity BioSciences is pleased to contribute a private-sector perspective on bridging science with practical commercialization pathways.

The conference offers a valuable opportunity for collaboration across the state’s hashtag#LifeSciences ecosystem, and Oscity looks forward to the exchange.

Event Details
Science Meets Strategy
Thursday, October 22, 2026 | 3:00 p.m.
Renaissance Birmingham Ross Bridge Golf Resort & Spa
Birmingham, Alabama

Learn more about the BIO Alabama 2026 Annual Conference: https://t.co/rTUQQdysBR

[Oscity BioSciences @oscitybiosci]

Why does a crystal structure matter if the active molecule is the same?

Cannabinoids are oily, light-sensitive, and poorly soluble in water. That is why oral products are inconsistent. Same milligram on the label. Different amount that actually reaches the patient. Different shelf life. Different batch.

A cocrystal does not change the pharmacology of the cannabinoid. It changes the conditions under which that pharmacology can be trusted.

In practical terms, the right cocrystal can help with four things that determine whether a therapy is usable:
1. Purity — the crystal can pull the target cannabinoid out of a complex extract in one step, often from crude material to pharmaceutical-range purity, without relying on heavy chromatography.
2. Stability — the ordered solid is less of a moving target than an oil. That matters for shelf life, heat, and manufacturing.
3. Consistency — one defined crystal fingerprint means the same solid form, batch after batch. Formulation teams can design around a known solid, not a variable resin.
4. Delivery potential — a more controlled solid is easier to build into tablets, capsules, and other pharmaceutical dosage forms. That is how we move from an extract to a product a healthcare provider can prescribe with confidence.

Enhanced therapeutic value, in this context, does not mean a magic new effect. It means the same active ingredient, in a form that can be purified, stored, dosed, and developed like a medicine.

That is the difference between a botanical ingredient and a pharmaceutical candidate.

[Oscity BioSciences @oscitybiosci]

Medicines can fail quietly when the dose is unpredictable.
Here is what the integration of Enantia’s cannabinoid co-crystal technology patents into Oscity BioSciences’ established cGMP foundation unlocks:

For patients – A defined solid form is one of the unglamorous requirements of a product that can work consistently day after day.  If cannabinoids are to deliver therapeutic value, consistency is not a luxury. It is the therapy.

For healthcare providers and developers – Co-formers such as L-proline are already familiar in food and pharma. We are not inventing a new chemical entity. We are putting a known active into a known class of solid form. That keeps the regulatory conversation on quality and performance, not on “what did you turn this molecule into.”

For manufacturing – Purification without chromatography, at commercial scale, is reality.  Our process takes input material to a high-purity solid at ordinary temperature and pressure.

For partners – Issued U.S. patents 11,168,047 and 11,993,563 cover characterized co-crystal forms across the cannabinoid landscape: CBD, CBG, CBN, CBDV, and related structures.  That is a platform, not just a single novelty compound.  Licensees and development partners can build products on protected ground.

At Oscity BioSciences, we are on a journey to develop cannabinoid medicines the way other serious drugs are developed: as defined solids, with a fingerprint, a process, and a path.

If you are working in formulation, CMC, or cannabinoid drug development and want the technical briefing behind our announcement, our team is available.

[Oscity BioSciences @oscitybiosci]

A recent study published in Pharmaceuticals highlights the therapeutic potential of Cannabigerol (CBG) in Rheumatoid Arthritis (RA). Key findings include:
* CBG significantly reduced pro-inflammatory cytokines from human neutrophils in a dose-dependent manner.
* In the arthritis model, CBG improved clinical scores, reduced joint inflammation, and lowered key cytokines.
* Strong evidence that CBG can modulate neutrophil activity and help regulate immune responses in RA.

At Oscity BioSciences, we’re actively advancing cannabinoid-based solutions. Our patented co-crystal technology is engineered to enhance stability, solubility, and oral bioavailability — critical for turning promising compounds like CBG and CBD into reliable medical therapies.

The future of cannabinoid medicine for RA and similar diseases is bright.
https://t.co/7OeDRuNoOS

[Oscity BioSciences @oscitybiosci]

What Is the Endocannabinoid System?

Have you ever wondered why your body can maintain balance amid constant change? Meet one of the most important systems you may never have learned about in school: the Endocannabinoid System (ECS).

Discovered in the early 1990s, the ECS is a complex cell-signaling network present throughout the human body...in the brain, immune cells, organs, connective tissues, and more. It consists of three core components:
• Endocannabinoids (naturally produced molecules such as anandamide and 2-AG)
• Cannabinoid receptors (primarily CB1, concentrated in the nervous system, and CB2, more prominent in the immune system)
• Enzymes that synthesize and break down these molecules on demand

Unlike many other systems, the ECS works as a master regulator that helps keep internal conditions stable. Phytocannabinoids (from plants) can interact with the same receptors, which is why research into cannabinoid-based therapeutics continues to expand.

At Oscity BioSciences, we believe understanding the ECS is the foundation for developing next-generation, precision cannabinoid medicines. A mission our team is dedicated to.

https://t.co/60hjLtonLr

[Oscity BioSciences @oscitybiosci]

What Does the Endocannabinoid System Do?

The human Endocannabinoid System (ECS) doesn’t just exist, it actively works every day to keep your body in balance (homeostasis).

When something disrupts equilibrium — stress, injury, inflammation, or environmental changes — the body produces endocannabinoids on demand.

These molecules bind to CB1 and CB2 receptors and help modulate:
• Mood and stress response
• Pain sensation
• Appetite and metabolism
• Immune function and inflammation
• Sleep, memory, and neurological signaling
• Reproductive and gastrointestinal processes

Because endocannabinoids are made only when needed and then rapidly broken down, the system is highly precise and self-regulating. Dysregulation of the hashtag#ECS has been linked to a wide range of conditions, which is why it has become a major focus of therapeutic research and product development.

This is the biological foundation that makes thoughtfully designed cannabinoid compounds so promising. hashtag#Oscity BioSciences is building on that science with proprietary approaches and patented products designed to engage the ECS more effectively.
https://t.co/60hjLtonLr

[Oscity BioSciences @oscitybiosci]

Why the Endocannabinoid System Matters?

The human endocannabinoid system (ECS) is often called one of the most important regulatory networks in the body, yet it remains under-recognized.

Its importance lies in its reach and its role as a bridge between body and mind. CB1 and CB2 receptors are distributed so widely that the hashtag#ECS influences nearly every major physiological process. When the system functions optimally, it supports resilience. When it is out of balance, research associates that imbalance with chronic pain, inflammatory conditions, neurodegenerative processes, mood disorders, sleep, and metabolic issues.

Because the ECS is so central to maintaining health, therapies that can gently and selectively support or modulate it hold significant therapeutic potential. Not all cannabinoid approaches are equal, however. Stability, purity, bioavailability, and how the compound interacts with the receptors matter greatly. Areas that Oscity BioSciences hashtag#cocrystal platform can address.

Scientific advancement in this space requires more than simply extracting plant compounds. It requires dedicated pharmaceutical-grade innovation that Oscity focuses on.
https://t.co/60hjLtonLr

[Oscity BioSciences @oscitybiosci]

We just announced the acquisition of Enantia’s cannabinoid cocrystal patents. So what actually is a cocrystal?

A cocrystal is not a new drug. It is not a blend. It is not a chemical rewrite of CBD, CBG, or any other cannabinoids. It is two known molecules that lock together in a precise crystal...the cannabinoid and a familiar, food-grade partner such as L-proline.

Raw cannabinoid oil is hard to purify, hard to dose the same way twice, and hard to keep stable. A cocrystal provides an ordered and consistent molecular structure. That ordered form is why pharmaceutical companies have used cocrystals for years in other drug classes. The FDA has already approved multiple cocrystal medicines. The science is not experimental. We are now applying it across the cannabinoid spectrum, with issued U.S. patents, and building upon that platform.

More to come on why that innovative form changes what a therapy can actually do.

[Oscity BioSciences @oscitybiosci]

We are proud to stand with Enantia on this announcement. Their pioneering work in pharmaceutical cocrystals has built a firm foundation for a purification and solid-form approach needed in this industry sector, and now accelerates our innovation around cannabinoid APIs at commercial scale.

Pairing Enantia’s deep solid-state expertise with these issued U.S. patents, Oscity’s cGMP-certified facility in Foley, and disciplined focus on consistent, chromatography-free cocrystals is a natural fit. Our team is grateful for the collaboration and looking forward to what we build next with partners who need pharmaceutical-grade cannabinoid forms.

https://t.co/SiGoCkbjeZ

[Oscity BioSciences @oscitybiosci]

Oscity BioSciences announces the acquisition of Enantia’s foundational U.S. cannabinoid cocrystal patents—Nos. 11,168,047 and 11,993,563—and the opening of a path for continued scientific cooperation.

Enantia originated the co-crystal science behind U.S. Patents 11,168,047 and 11,993,563. These issued claims cover defined cannabinoid cocrystals, including CBD, CBG, CBN, CBDV, and related molecules with selected co-formers, with processes for their preparation and purification. The technology enables chromatography-free purification and solid forms with the stability, consistency, and developability required for pharmaceutical-grade APIs, and is now being advanced at our cGMP-certified facility in Foley, Alabama.

This relationship connects two decades of Barcelona solid-state expertise with a U.S. manufacturing and licensing platform built for pharmaceutical-grade cannabinoid APIs. One defined polymorph. No chromatography. GRAS co-formers. A clearer path from extract to consistent, developable solid form. Together we intend to advance research, scale production, and explore pharmaceutical applications of these solid forms.

We are grateful to Enantia team for the science that made this possible. We look forward to the work ahead and the responsible development of these assets.

Read the full announcement:
https://t.co/0w5vfMOJTt

[Oscity BioSciences @oscitybiosci]

The Oscity BioSciences team is honored to be part of Biotech Cohort III with Hatch Fairhope Powered by Bessel. Our company's accelerating growth will no doubt greatly benefit from the disciplined program you have developed through the years. Thank you for the opportunity Hatch Fairhope and Bessel.

https://t.co/8SuSwLi4hd

[Oscity BioSciences @oscitybiosci]

The Oscity BioSciences team is honored to be represented in this next Hatch Fairhope Powered by Bessel Biotech cohort. Our growing company will benefit greatly from participating in this established program, with such a stellar group. Thank you Hatch Fairhope and Bessel.

https://t.co/Q644PWmRHQ

[Oscity BioSciences @oscitybiosci]

Oscity BioSciences: Proprietary, Patented Cannabinoid Solutions

Understanding the endocannabinoid system is only the beginning. The real opportunity lies in developing cannabinoid-based products that can work with it more effectively and deliver meaningful therapeutic value.

Oscity BioSciences is focused on exactly that. We are advancing proprietary, patented technologies centered on cannabinoid cocrystals, including our L-proline cocrystals covered by U.S. patents 11,168,047 and 11,993,563. These innovations address key limitations of traditional cannabinoid forms: improved solid-state properties, enhanced purity pathways, greater stability, and the potential for better formulation and delivery characteristics needed for pharmaceutical and advanced therapeutic applications.

Our platform is designed to support the development of high-purity isolates and specialized formulas (including those aimed at inflammatory, hashtag#autoimmune, and related conditions) that can more reliably engage the body’s own endocannabinoid system. In our cGMP-certified facility, we are building toward scalable manufacturing and rigorous regulatory pathways so that these proprietary compounds can move from science into real-world therapeutic value.

The endocannabinoidsystem is fundamental. Oscity BioSciences is committed to developing the next generation of tools that work with it.
https://t.co/vhzGog4aEW

[Oscity BioSciences @oscitybiosci]

Our team is excited to be part of Baldwin County's growing BioTech Ecosystem on the Gulf Coast, and we greatly appreciate the support from and engagement with Hatch Fairhope and Baldwin Alliance. Thank you for the visit.

https://t.co/X6lSVc5wgc

[Oscity BioSciences @oscitybiosci]

New research highlights the power of cocrystals for CBD.

Cocrystals are generating serious interest in pharmaceutical and nutraceutical development, and for good reason.  Many are curious about cocrystals and the advantages they offer.

A 2025 study published in CrystEngComm evaluated five CBD co-crystals designed to address CBD's well-known formulation challenges: low melting point, poor stability, and limited shelf life.

Every cocrystal tested melted at a higher temperature than pure CBD. Two performed especially well. The CBD-L-proline form stood out, remaining stable significantly longer than pure CBD under accelerated heat and humidity stress conditions.

The conclusion is straightforward: the right co-former meaningfully improves a cannabinoid's solid-state stability and handling properties.

This is precisely the foundation of Oscity BioSciences' patented approach. Our two granted U.S. patents, US 11,168,047 and US 11,993,563, cover co-crystal solid forms across the full cannabinoid spectrum using L-proline as the co-former, producing a single defined polymorph with consistent stability and dissolution characteristics that pure CBD and standard distillates cannot match.

The science is there. The IP is granted. The conversation is just getting started.
https://t.co/60hjLtonLr

https://t.co/KYRvb31W9O